Global Community

Rating: Speculative Buy / Clinical-event driven Style: Small-cap biotech with one dominant value driver Core debate: Is Newron an underappreciated CNS biotech on the verge of a value inflection with evenamide, or is it still a one-asset, high-risk Phase III story where financing and trial execution dominate everything else? Executive view Newron is now essentially an evenamide company.Read more

Rating: Buy / Quality recovery compounder Style: Mid-cap consumer compounder with cyclical film-slate exposure Core debate: Is Kinepolis just a movie-theatre operator in a structurally challenged industry, or is it a premium cinema platform with better economics, stronger pricing power, and more durable cash generation than the market gives it credit for? Executive view Kinepolis is not a “cinema recovery trade” in the simple sense.Read more

Pagaya Technologies (NASDAQ: PGY) — Investment Thesis Pagaya Technologies is not a software company. This distinction is the foundation of the entire investment case and is widely misunderstood by the market.Read more

Successful ad networks are driven fundamentally by usage. The best type of usage is on returning daily users usually measured by Daily Active Users.Read more

Silver X Mining Corp. (TSXV: AGX) Disclaimer This material is provided for informational and educational purposes only and should not be considered financial, investment, legal, tax, or other professional advice.Read more

Cochlear Limited is an interesting company. It is a medical technology business with a specific focus on implantable hearing solutions.Read more

Valuation In 3–5 years, I think Microsoft becomes even more dominant in enterprise AI, cloud infrastructure, and productivity software. Azure and Copilot are probably the biggest growth drivers, while Windows, Office, LinkedIn, GitHub, and gaming remain huge cash generators.Read more

Rating: Speculative / Venture-style public equity Style: Pre-revenue aerospace development story Core debate: Is Horizon Aircraft a differentiated eVTOL platform with a more practical mission profile than many peers, or is it still too early, too capital-intensive, and too uncertain to justify meaningful equity upside today? Executive view Horizon Aircraft is not an established aerospace manufacturer.Read more

Rating: Speculative Buy / High-risk value Style: Leveraged offshore E&P recovery Core debate: Is Kosmos just another debt-heavy small-cap oil and gas producer, or is it an underappreciated offshore cash-flow story with improving production, falling costs, and meaningful equity upside if management keeps deleveraging? Executive view Kosmos is not a “quality compounder” in the way Prysmian or Quanta are.Read more